Anna‐Maria Fink

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo et al. · The Lancet Oncology · 2016 · 613 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Kirsten Fischer, Paula Cramer, Raymonde Busch et al. · Journal of Clinical Oncology · 2012 · 429 citations · Full text

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Barbara Eichhorst, Raymonde Busch, Stephan Stilgenbauer et al. · Blood · 2009 · 333 citations

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater et al. · New England Journal of Medicine · 2023 · 268 citations · Full text

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

Othman Al‐Sawaf, Can Zhang, Tong Lu et al. · Journal of Clinical Oncology · 2021 · 132 citations · Full text